GlassScriptPhysician profile
Erin Perdue
NPI 1275949455
$7,654.54
in general payments reported to CMS, 2019-2025
34 companies · $996 in 2025
The $996 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,600 · 2022: $1,670 · 2023: $1,622 · 2024: $1,767 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,251.54 |
| Education | $132.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,151.23 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,104.98 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $818.70 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $626.88 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $483.89 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.47 | 2021-2023 | Stiolto Respimat, Ofev |
| Mallinckrodt Hospital Products INC. | $310.93 | 2021-2025 | Acthar, Terlivaz |
| United Therapeutics Corporation | $283.88 | 2021-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $258.35 | 2021-2024 | |
| Amgen INC. | $230.19 | 2022-2025 | Tezspire |
| Philips North America LLC | $225.04 | 2021-2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $220.53 | 2022-2025 | Glassia |
| Mylan Specialty L.P. | $178.30 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.64 | 2021-2024 | |
| Grifols USA, LLC | $158.55 | 2023-2024 | Prolastin-C Liquid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $132.98 | 2023-2025 | |
| Gilead Sciences, INC. | $116.41 | 2021-2023 | |
| Verona Pharma, INC. | $106.57 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $93.65 | 2021-2023 | Wakix |
| Vifor Pharma, INC. | $73.78 | 2024 | Zemaira |
| Janssen Pharmaceuticals, INC | $71.05 | 2021-2022 | |
| Baxter Healthcare | $61.95 | 2022-2025 | Fluid Systems - Premix Drugs |
| Pharming Healthcare, INC. | $48.20 | 2023 | Ruconest |
| Axsome Therapeutics, INC. | $47.30 | 2023-2025 | Sunosi |
| Pfizer INC. | $46.88 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $39.44 | 2022 | |
| Genentech USA, INC. | $29.53 | 2024 | Xolair |
| Merck Sharp & Dohme LLC | $27.27 | 2025 | Keytruda |
| Boston Scientific Corporation | $21.90 | 2023 | Ekosonic |
| Shionogi INC | $20.72 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.33 | 2021 | |
| Resmed Corp | $16.77 | 2023 | |
| Electromed, INC. | $15.50 | 2024 | Smartvest |
| 3b Medical, INC. | $6.75 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Perdue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.